Standardized Pathogen Inactivation Compound for Platelet Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pathogen inactivation in platelet preparations lack flexibility and efficiency, particularly in apheresis-derived preparations, due to variable donation volumes and platelet numbers, which can impact the consistency and effectiveness of pathogen removal.
Innovation Solution
A method involving the combination of a platelet additive solution (PAS) and a pathogen inactivation compound (PIC), such as amotosalen, which is pre-mixed to a standardized concentration and then admixed with platelets, followed by exposure to light for photochemical inactivation, allowing for consistent pathogen inactivation across varying donation volumes and platelet numbers without the need for additional processing steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pathogen inactivation is performed using compound-based methods with guard band ranges for input platelet volumes and platelet numbers, then pathogen inactivation effectiveness is improved, but processing flexibility and productivity deteriorate due to variable donation volumes and platelet numbers
Solution Approach 1:
The patent changes the concentration parameter of the pathogen inactivation compound to a standardized fixed concentration (e.g., 225-235 μM amotosalen) regardless of donation volume or platelet number variations. This parameter standardization eliminates the need for guard band ranges and complex calculations, allowing consistent pathogen inactivation across variable donations while improving processing flexibility and productivity
Solution Approach 2:
The patent creates a universal pathogen inactivation protocol that works across all donation types (apheresis-derived and whole blood-derived platelets) with varying volumes and platelet numbers. The standardized compound concentration and fixed processing time create a multi-functional solution that handles diverse donation scenarios without requiring separate protocols or adjustments
2Reliability
If higher concentrations of pathogen inactivation compound are used to ensure pathogen inactivation, then pathogen inactivation effectiveness is improved, but impact on platelet function increases
Solution Approach 1:
The patent optimizes the concentration parameter of the pathogen inactivation compound to a specific range (225-235 μM amotosalen) that achieves effective pathogen inactivation while minimizing impact on platelet function. This precise parameter control balances effectiveness with preservation of platelet functionality
Solution Approach 2:
The patent applies a fixed, standardized concentration of pathogen inactivation compound that is sufficient to achieve the required level of pathogen inactivation (partial action) without using excessive amounts that would harm platelet function. The standardized concentration ensures adequate inactivation while avoiding over-treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures consistent pathogen inactivation, reducing the amount of PIC required, eliminating the need for compound absorption devices, and providing standardized treatment conditions, thereby enhancing the flexibility and productivity of pathogen inactivation systems.
Implementation Method 1
subjecting the admixture of step (b) to light sufficient to photochemically inactivate a pathogen, if present
Data Source
AI summary
Provided are methods, kits, and compositions for preparing platelet compositions suitable for infusion, including improved methods, compositions, and kits for pathogen inactivation of an apheresis-derived preparation of platelets.